Granules India receives approval from Brazilian Health Regulatory Agency
Hyderabad: Granules India Limited has announced the receipt of the approval from Brazilian Health Regulatory Agency (ANVISA), for compliance with the guidelines of Good Manufacturing Practices for its Bonthapally facility, located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Hyderabad, Telangana.
Bonthapally facility manufactures Active Pharmaceutical Ingredients (API).
Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered at Hyderabad. The company is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Its products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, U.S. and U.K. The Company has 8 manufacturing facilities out of which 6 are located in India and 2 are in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.
Read also: USFDA nod to Granules India Metoprolol Succinate ER Tablets
